Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients

RATIONALE: Extended-release naltrexone (XRNT), an opioid receptor antagonist, is successfully used in the treatment of opioid dependence. However, naltrexone treatment of opioid-dependent patients may reduce striatal dopamine transporter (DAT) availability and cause depression and anhedonia. OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaaijer, Eline R., van Dijk, Lonneke, de Bruin, Kora, Goudriaan, Anna E., Lammers, Laureen A., Koeter, Maarten W. J., van den Brink, Wim, Booij, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480848/
https://www.ncbi.nlm.nih.gov/pubmed/25757673
http://dx.doi.org/10.1007/s00213-015-3891-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480848/
https://www.ncbi.nlm.nih.gov/pubmed/25757673
http://dx.doi.org/10.1007/s00213-015-3891-4

Ejemplares similares